Special Issue "Update on COPD and Cystic Fibrosis"
Deadline for manuscript submissions: 10 March 2024 | Viewed by 5497
Interests: inflammatory lung diseases; aging; fibroblast growth factor signaling; klotho; cystic fibrosis; chronic obstructive pulmonary disease; pulmonary vascular remodeling; fibroblast growth factor 23
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Therapeutic Approaches for Aging-Related Lung Disease
Topical Collection in International Journal of Molecular Sciences: State-of-the-Art Molecular Mechanisms of Pulmonary Pathology in USA
Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are two chronic inflammatory lung diseases, which seem to be very different from each other.
COPD, known as a chronic airway disease strongly associated with smoking, is currently the third leading cause of death, with a high socioeconomical burden due to the number of people affected, which is more than 65 million. Despite the availability of therapies mainly addressing symptoms, there is lack of access for many patients, and more research is needed to help to prevent the development of respiratory symptoms, better characterize COPD itself, provide equal access for patients, and finally identify novel therapies.
CF research has experienced a revolution over the last decade due to the development of therapies including the highly effective modulator therapy (HEMT) leading to a substantial increase in life expectancy and quality of life for people with CF (pwCF). Unfortunately, we have still not found a cure due to missing 10% of CFTR mutations, which do not respond to HEMT and pwCF with existing CF-related disease, who are now aging and potentially developing more and new comorbidities.
The aim of this Special Issue of Medicina is to showcase new advances in the field of cystic fibrosis and COPD research. This Special Issue is open to basic research, clinical and translational studies, case reports, perspectives, reviews, and systematic reviews and meta-analyses.
The aim of this Special Issue will be to deliver new insights into the evolving field of CF and COPD research. Manuscripts focused on the following topics are strongly encouraged.
- Novel therapeutic strategies in CF and COPD;
- Chronic inflammation and infections in CF and COPD;
- Disparity research in COPD;
- Aging in COPD and CF;
- Access to care for patients with CF and COPD.
Dr. Stefanie Krick
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cystic fibrosis
- airway disease